On March 19, 2026, Eli Lilly reported that retatrutide — its next‑generation obesity therapy — met the primary and key secondary endpoints in a first late‑stage trial among people with Type 2 diabetes. In the 40‑week study, retatrutide lowered hemoglobin A1c by an average of 1.7%–2.0% across doses versus placebo and produced substantial weight loss at the highest dose. Participants entered the trial with baseline A1c between 7.0% and 9.5% and were not on other diabetes medications. Lilly said discontinuation for adverse effects was relatively low, up to 5% at the highest dose.
Key takeaways
- Primary endpoint: retatrutide reduced hemoglobin A1c by 1.7%–2.0% versus placebo at 40 weeks across dose groups.
- Weight loss (completers): the highest dose delivered an average 16.8% weight reduction (about 36.6 lb) at 40 weeks among patients who remained on therapy.
- Weight loss (all participants): in an intent‑to‑treat analysis including discontinuations, the highest dose produced 15.3% average weight loss at 40 weeks.
- Baseline population: enrolled patients had A1c between 7.0% and 9.5% and were not taking other glucose‑lowering drugs.
- Safety: discontinuation due to side effects was up to 5%; common adverse events at the highest dose included nausea (26.5%), diarrhea (22.8%) and vomiting (17.6%).
- Mechanism: retatrutide is a triple agonist that mimics GLP‑1, GIP and glucagon, distinguishing it from single‑ or dual‑hormone agents.
- Regulatory status: Lilly has not yet filed for approval in obesity or diabetes and expects results from seven additional phase 3 trials by year end.
Background
Pharmaceutical attention on obesity and metabolic disease has surged as new injectables and oral agents deliver unprecedented weight loss and glycemic control. Eli Lilly already markets tirzepatide under the weight‑loss brand Zepbound and is developing an oral candidate, orforglipron; retatrutide is positioned as a potential next pillar in that portfolio. The industry is moving from single‑hormone GLP‑1 agonists to multi‑agonist molecules designed to broaden effects on appetite, energy expenditure and glucose regulation.
Historically, patients with Type 2 diabetes face particular difficulty achieving meaningful weight loss, complicating glucose management and cardiovascular risk reduction. In recent years, trials have reported both glycemic and weight benefits from agents such as tirzepatide (Zepbound) and semaglutide (Wegovy), prompting payers, clinicians and regulators to reassess treatment algorithms. Manufacturers are racing to demonstrate differentiated efficacy, acceptable safety and real‑world durability to capture large patient populations.
Main event
The trial reported by Lilly ran to 40 weeks and enrolled adults with Type 2 diabetes whose baseline hemoglobin A1c ranged from 7.0% to 9.5%; participants were not permitted other diabetes medications during the study. Across dose groups, retatrutide met the predefined primary endpoint by lowering A1c an average of 1.7%–2.0% compared with placebo. The highest dose produced the largest glycemic effect and the most pronounced weight loss.
Weight outcomes at the 40‑week mark were notable: among those who stayed on treatment, patients on the top dose lost on average 16.8% of body weight (about 36.6 pounds). When the analysis included all randomized participants, accounting for discontinuations, the highest dose resulted in 15.3% average weight loss. Lilly emphasized both sets of figures in describing efficacy.
Safety observations were consistent with other injectables that act on gut‑related pathways. The company reported gastrointestinal side effects as the most frequent events: nausea occurred in 26.5% of patients at the highest dose, diarrhea in 22.8% and vomiting in 17.6%. Dysesthesia was reported in small numbers. Lilly highlighted a relatively low overall discontinuation rate for adverse events, up to 5% at the highest dose.
Analysis & implications
Clinically, the combination of robust A1c lowering and large absolute weight loss is attractive because it addresses two central challenges in Type 2 diabetes: glycemic control and obesity‑related comorbidity. For many patients, therapy that improves both metrics could reduce the need for additional glucose‑lowering drugs and may affect cardiovascular and renal outcomes, though those benefits require dedicated outcome studies. The magnitude of weight loss reported — mid‑teens percentage points at 40 weeks — places retatrutide among the most potent agents tested to date.
From a commercial perspective, Lilly is expanding its obesity and cardiometabolic franchise at a time when demand and scrutiny are both high. The company is scaling manufacturing, including a planned $6.5 billion Texas facility for obesity therapies, and is preparing for multiple regulatory filings once pivotal programs complete. Payers will evaluate cost, long‑term safety and comparative effectiveness in setting coverage policies; absence of head‑to‑head data will complicate immediate positioning against rivals.
Competition is intensifying. Novo Nordisk and others are developing multi‑agonist candidates that could rival retatrutide, but timelines differ: some competitors are earlier in clinical development and will not reach patients for years. The lack of direct comparative trials means clinicians will need to consider individual patient priorities — whether glycemic control, maximal weight loss, tolerability or route of administration — when selecting therapies.
Comparison & data
| Agent | A1c reduction at 40 weeks | Weight change at 40 weeks (top dose) | Notable safety signals |
|---|---|---|---|
| Retatrutide (Lilly) | 1.7%–2.0% vs placebo | 16.8% (completers); 15.3% (all participants) | Nausea 26.5%, diarrhea 22.8%, vomiting 17.6%; discontinuation ≤5% |
| Zepbound / tirzepatide (Lilly) | >2.0% in two diabetes trials | 13.1% (SURPASS‑2); 11.0% (SURPASS‑1) | GI adverse events; class‑typical profile |
| Semaglutide / Wegovy (Novo Nordisk) | Variable by trial; GLP‑1 single agonist | Lower than multi‑agonists in comparable studies | GI adverse events; injection site reaction |
The table places the new retatrutide results alongside earlier Lilly data for tirzepatide and general characteristics for semaglutide. Direct cross‑trial comparisons have limits due to differing populations, trial designs and analytic approaches; head‑to‑head studies would be required for definitive ranking.
Reactions & quotes
Lilly executives framed the results as a validation of the triple‑agonist approach and said the balance of efficacy and tolerability supports further development across indications. They also underscored the need for multiple options to meet diverse patient goals.
“We are very excited to see both competitive blood sugar reductions and significant weight loss with retatrutide,”
Ken Custer, President, Lilly Cardiometabolic Health
In discussing clinical positioning, company leadership noted that different patients may prioritize weight loss or glucose control, and that retatrutide could be selected for those seeking larger weight reductions. They cautioned that regulatory filings have not yet been submitted.
“The A1c reduction is very, very strong compared with medications that do not target gut hormones, and having multiple options is important because not everybody will be helped or satisfied with the same treatment,”
Ken Custer, Lilly Cardiometabolic Health
Independent clinicians and health‑system leaders will watch upcoming phase 3 readouts and future safety datasets before altering prescribing patterns. Payers and guideline bodies will take a measured approach until long‑term outcomes and comparative effectiveness are clear.
Unconfirmed
- No head‑to‑head trials have yet compared retatrutide directly with other multi‑agonists or with tirzepatide; comparative superiority is unconfirmed.
- Durability of weight loss and glycemic control beyond the 40‑week window remains unproven until longer‑term data are reported.
- Regulatory timelines and labeling for obesity versus diabetes indications are not finalized; filing dates have not been announced.
Bottom line
Retatrutide’s first late‑stage diabetes readout shows both meaningful A1c reductions and large weight losses at 40 weeks, reinforcing the promise of multi‑agonist therapies for people with Type 2 diabetes and obesity. The safety profile appears broadly consistent with other agents in the class, with gastrointestinal side effects most commonly reported and modest discontinuation rates reported by Lilly.
Key next steps to watch are results from the seven additional phase 3 trials Lilly expects to report by year end, any regulatory filings the company submits, and real‑world tolerability and outcomes assessed by payers and guideline panels. Until head‑to‑head data and longer‑term outcomes are available, clinicians will need to weigh individual patient goals and tolerability when choosing among expanding therapeutic options.